Our Research Results

Since we first began more than 40 years ago, Breast Cancer Trials (BCT) has contributed to more than 1,200 peer-reviewed publications and many of these research results have changed practice in the treatment and prevention of breast cancer.

The publication of the results of clinical trials research in a scientific journal or a periodic publication:

  • Fulfils the researchers’ ethical obligations to research participants and the general community;
  • Contributes to medical knowledge so doctors can make scientifically valid assessments of the benefits and risks of a new medicine or treatment for their patients.

BCT publishes study results in accordance with the BCT Publication Policy.

The citations for all of these publications are listed below, ordered by year. To search for a citation, enter a keyword/s and click search. Enclose multiple words in quotes “” to search for an exact match. Alternatively, you can search for clinical trials in a given year or for a particular clinical trial name. 

The majority of the publications can be accessed via PubMed, other research databases or publication storage systems at a university library (if you are a student/member), or directly to the journal or publication online. Many scientific journals provide articles as “open access”; however some require a subscription.

PUBLICATIONS

2025

Stabilised hyaluronic acid gel marker versus surgical clips for tumour bed delineation in breast cancer radiotherapy using MRI-simulation [BCT Clinical Fellowship].

Yeh J, Tacey M, Harris B, Lau E, Lapuz C, Pignol J-P, Foroudi F, Mathieu D, Fong SC, Ng, SP, Sim J, Chao J. Radiotherapy and Oncology. 2025; 205110749. epub 27 Jan 2025.:1-7, https://doi.org/10.1016/j.radonc.2025.110749, E-pub

2024

The complexities of establishing a surgical multi-centre registry in Australia: challenges, and possible solution. [BCT Clinical Fellowship].

Ofri A, Spillane A. ANZ Journal of Surgery. 2024; 94(9):1444-1446, DOI: 10.1111/ans.19157, Journal

AFT-38 PATINA: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor-Positive (HR+)/HER2-Positive Metastatic Breast Cancer.

Metzger O, Mandrekar S, DeMichele A, Gianni L, Gligorov J, Lim E, Ciruelos E, Loibl S, Dockter T, Gonzalez Farre X, Francis P, Lynce F, Lanzillotti J, DuFrane C, Drop I, Vaz-Luis I, Valagussa P, Tripathy D, Soi S, Prat A, Goetz M, Escriva-de-Romani S, Porter D, Spoenlein J, Saresai S, Heudel P, Koehler M, Huang Bartlett C, Hoynskyj A, Copalakrishna P, Gauthier E, Liu Y, Slaloge S, Miller K, Winer E, Partridge A, Goel S, Carey L. SABCS 2024; Abstract

OlympiA: A phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w/ germline BRCA1 & BRCA2 pathogenic variants & highrisk HER2-negative primary breast cancer: longerterm follow

Garber, J. SABCS 2024; GS1-09, Abstract

Breast Cancer Trials Consumer Advisory Panel: An established model for improving consumer engagement in research.

Gilham L, Alexander K, Angus R, Carter M, Crowley E, McCambridge L, Nekkalapudi N, Badger H. ACTA 2024; Poster

De-escalation of chemotherapy in patients with HER2-positive, hormone receptor negative, node negative early breast cancer: primary results of the phase II DECRESCENDO trial.

Agostinetto E, Adam V, Cambier S, Birta O, Velghe C, Correia de Nobrega VS, Arecco L, Callens C, Deluche E, Brain E, Gennari A, Phillips K-S, Kim JH, Gal-Yam E, Gelham L, Needham J, Bedard PL, Connolly RM, Romera A, Vincent-Salomon A, Zoppoli G, Piccart M. San Antonio Breast Cancer Symposium. 2024; P3-11-03, Poster

Total Publications: 1327